Profound Hair and Skin Hypopigmentation in an African American Woman Treated With the Multi-Targeted Tyrosine Kinase Inhibitor Pazopanib
- 1 July 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (19) , e312-e313
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Sunitinib and Periodic Hair Depigmentation Due to Temporary c-KIT InhibitionArchives of Dermatology, 2008
- Vitiligo‐Like Lesions and Diffuse Lightening of the Skin in a Pediatric Patient Treated with Imatinib Mesylate: A Noninvasive Colorimetric AssessmentPediatric Dermatology, 2006
- Imatinib mesylate causes hypopigmentation in the skinCancer, 2003
- Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and HumansThe Journal of Pharmacology and Experimental Therapeutics, 2003
- A novel KIT mutation results in piebaldism with progressive depigmentationJournal of the American Academy of Dermatology, 2001
- AUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMACytokine, 2000
- Inhibition of Proliferation of Human Melanocytes by a KIT Antisense Oligodeoxynucleotide: Implications for Human Piebaldism and Mouse Dominant White Spotting (W)Journal of Investigative Dermatology, 1994
- White Mutants in Mice Shedding Light on HumansJournal of Investigative Dermatology, 1993
- Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism.Proceedings of the National Academy of Sciences, 1991